RapidAIM ®
A high-throughput microbiome platform to assess drug-microbiome interactions

The RapidAIM technology allows the rapid screening of compounds against individual human microbiomes and greatly accelerates the discovery of compounds that target the human microbiomes. Our current technology can also be used to de-risk compounds, stratify patients based on their microbiome responses and other applications.


Using RapidAIM, MedBiome is focusing on the development of compounds that modulate the production of specific metabolites by the human microbiome, specific microbial pathways and enzymes.